Consultation record
Submissions noted, no amendment — page 2
The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Submissions
109 documents · page 2 of 4
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-TOOLS-DISCLA/014 | Draft terms for the Institute’s calculators | Dr Beatrijs Hazelrigg | Assessment committee meetings are held in private |
| DRAFT-TOOLS-DISCLA/018 | Draft terms for the Institute’s calculators | Dr Perpetua Haverkamp-Diallo industry | The disclosure requirements exceed those of comparable bodies |
| DRAFT-DANUGLIPRON-/003 | Draft monograph: danuglipron | Dr Rurik Haverkamp-Diallo | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-METHODOLOGY-/011 | Draft methodology document, version 4 | Dr Delphine Trelawney | The document should describe how an assessment becomes a decision |
| DRAFT-METHODOLOGY-/017 | Draft methodology document, version 4 | Dr Emiliana Ollerenshaw | Declared interests should appear on the document rather than on a separate page |
| DRAFT-SUPPLIERS-CO/007 | Draft supplier comparison table | Wilhelmina Oppenheimer-Ade | A multi-part document does not indicate how many parts it has |
| DRAFT-SUPPLIERS-CO/009 | Draft supplier comparison table | Dr Georgiana Mountstephen | Declared interests should appear on the document rather than on a separate page |
| DRAFT-RETATRUTIDE-/011 | Draft monograph: retatrutide | Dr Constança Glendinning-Uche | A sortable table implies a comparison the underlying data do not support |
| DRAFT-SEARCH-STRAT/005 | Draft search-strategy template for the synthesis series | Dr Beatrijs Hazelrigg | A sortable table implies a comparison the underlying data do not support |
| DRAFT-PRINT-AND-AR/004 | Draft print and archival format for Institute documents | Dr Evander Ashworth-Danquah | Assessment committee meetings are held in private |
| DRAFT-CERTAINTY-IN/011 | Draft certainty index | Stellan Cholmondeley-Ade | A long index is paginated in a way that makes an item hard to find again |
| DRAFT-5-AMINO-1MQ-/003 | Draft monograph: 5-amino-1MQ | Dr Liesbeth Nyquist-Obiora | Guidance on lyophilised storage is missing |
| DRAFT-5-AMINO-1MQ-/006 | Draft monograph: 5-amino-1MQ | Dr Georgiana Mountstephen | Declared interests should appear on the document rather than on a separate page |
| DRAFT-AOD-9604-MON/011 | Draft monograph: AOD-9604 | Vittoria Ylönen | Declared interests should appear on the document rather than on a separate page |
| DRAFT-AOD-9604-MON/017 | Draft monograph: AOD-9604 | Dr Quentin Enthoven | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-CAGRISEMA-MO/003 | Draft monograph: CagriSema (cagrilintide with semaglutide) | Dr Evander Ashworth-Danquah | A sortable table implies a comparison the underlying data do not support |
| DRAFT-CAGRISEMA-MO/004 | Draft monograph: CagriSema (cagrilintide with semaglutide) | Dr Georgiana Mountstephen | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-CJC-1295-MON/010 | Draft monograph: CJC-1295 | Georgiana Zimmerthal | Declared interests should appear on the document rather than on a separate page |
| DRAFT-ECNOGLUTIDE-/005 | Draft monograph: Ecnoglutide | Quentin Whitmarsh-Obi | A superseded version should remain reachable from the version that replaced it |
| DRAFT-EPITHALON-MO/002 | Draft monograph: Epithalon | Dr Emiliana Ollerenshaw | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-GHK-CU-MONOG/003 | Draft monograph: GHK-Cu | Eamon Sandringham-Adu | A superseded version should remain reachable from the version that replaced it |
| DRAFT-GHK-CU-MONOG/005 | Draft monograph: GHK-Cu | Dr Emiliana Ollerenshaw | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-GHRP-6-MONOG/004 | Draft monograph: GHRP-6 | Dr Abimbola Sotomayor-Ekwueme | Guidance on lyophilised storage is missing |
| DRAFT-GLUTATHIONE-/003 | Draft monograph: Glutathione | Dr Vasilisa Sandringham-Adu | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-GLUTATHIONE-/013 | Draft monograph: Glutathione | Dr Rurik Haverkamp-Diallo | Declared interests should appear on the document rather than on a separate page |
| DRAFT-GONADORELIN-/003 | Draft monograph: Gonadorelin | Dr Rurik Haverkamp-Diallo | Declared interests should appear on the document rather than on a separate page |
| DRAFT-HEXARELIN-MO/006 | Draft monograph: Hexarelin | Dr Xenia Nyquist-Obiora | Guidance on lyophilised storage is missing |
| DRAFT-IGF-1-LR3-MO/004 | Draft monograph: IGF-1 LR3 | Dr Emiliana Ollerenshaw | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-IPAMORELIN-M/005 | Draft monograph: Ipamorelin | Dr Vasilisa Sandringham-Adu | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-KISSPEPTIN-1/003 | Draft monograph: Kisspeptin-10 | Dr Rurik Haverkamp-Diallo | The monograph should not describe how the compound is supplied outside a regulated route |
page 2 of 4